Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; Representative Director: Hiroshi Miyake), a venture company that leverages the results of research at Kyoto University, announces that it has entered into an exclusive agreement with Ono Pharmaceutical Co. Chordia has entered into an exclusive license agreement with Ono Pharmaceutical Industry for the worldwide development, manufacture and commercialization of Chordia's MALT1 inhibitor CTX-177 and related compounds. (headquartered in Sakyo-ku, Kyoto, Japan, CEO: Kusumi Kusumi, hereinafter referred to as "Kyoto iCAP"), with Kyoto University Innovation Capital Co.

Chordia grants Ono the exclusive worldwide rights to develop, manufacture and commercialize CTX-177 and related compounds. Chordia will receive an upfront payment of 3.3 billion yen (including an upfront payment of 0.8 billion yen) and milestone payments of up to 49.6 billion yen based on the progress of development and sales of the product. After the product is launched, Ono will receive royalties in the high single-digit to low double-digit range based on worldwide sales of CTX-177.

We are very pleased to partner with Ono, a leading oncology company with a unique and innovative portfolio of oncology drugs, for CTX-177, a MALT1 inhibitor. We are very pleased to partner with Ono, a leading oncology company with a unique and innovative portfolio of anti-cancer drugs, on our MALT1 inhibitor CTX-177. We are proud to have discovered CTX-177, a selective and potent MALT1 inhibitor, as part of our ongoing research and development of anti-cancer drugs with novel mechanisms of action. We hope that this partnership will help CTX-177 reach cancer patients with diverse needs more quickly."

We hope that this license agreement will accelerate the research and development of the MALT1 inhibitor CTX-177 and make it a new treatment option for cancer patients as soon as possible," said Kusumi Ko, President of Kyoto iCAP. The MALT1 inhibitor was also developed through an industry-government-academia effort involving Kyoto University. Kyoto iCAP hopes that this initiative will serve as a model for innovation in Japan. said Dr. K. Kato, President and CEO of Kyoto iCAP.

About the CTX-177
CTX-177 is a selective inhibitor of Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which is known to be involved in intracellular signal transduction in lymphoid blood cells, Activation of MALT1 has been reported to be important in the tumorigenesis of lymphoid blood cells, and CTX-177 is expected to have anti-tumor effects against these lymphoid blood cancers by inhibiting MALT1 activity.

This research on MALT1 inhibitors was initiated as an industry-academia-government collaboration with Takeda Pharmaceutical Company Limited ("Takeda"), Kyoto University, and Miyazaki University, supported by the Industry-Academia Medical Innovation Creation Program of the Japan Agency for Medical Research and Development ("AMED") Chordia has Chordia received a license from Takeda to conduct compound optimization research and discovered CTX-177. Subsequently, with the support of AMED's Innovative Cancer Therapy Practical Application Research Project, the National Cancer Center joined the collaboration and is conducting preclinical studies toward the start of clinical trials. The results of these preclinical studies of CTX-177 were presented at the 62nd Annual Meeting of the American Society of Hematology and Oncology, which was recently held from December 5 to 8, 2012. （Abstract #141824, Daisuke Morishita et.al. Abstract #141824: Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/ (Abstract #141824, Daisuke Morishita et al.)

About 0Chordia Therapeutics, Inc.
Chordia was established in November 2017 in the Shonan Health Innovation Park in Fujisawa, Kanagawa Prefecture as a research and development bio-venture specializing in oncology, with the goal of researching and developing anti-cancer drugs with novel mechanisms of action and creating innovative new drugs. Chordia is conducting Phase I clinical trials for its lead program, CTX-712, a CLK inhibitor, which targets a vulnerability in cancer and is expected to be an effective therapeutic agent. Chordia is conducting research and development for several pipelines that are expected to be effective in the treatment of cancers with specific abnormalities.

For more information, please contactthis way (direction close to the speaker or towards the speaker)for more information.